drugset / Trial / NCT03989544

A Study to Evaluate the Pharmacokinetics of Tezepelumab After Being Delivered by an Accessorized Pre Filled Syringe or Autoinjector Compared With Vial and Syringe in Healthy Adult Subjects

NCT03989544

Phase 1 Completed 315 enrolled AstraZeneca Amgen · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a study to compare PK of tezepelumab exposure in healthy subjects by using vial and syringe, APFS, and AI.

Timeline

Start
2019-06-19
Primary completion
2019-12-30
Completion
2019-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tezepelumab Monoclonal antibody 210 mg Subcutaneous

Indications